tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH

21.150USD

-0.060-0.28%
取引時間 ET15分遅れの株価
1.01B時価総額
7.12直近12ヶ月PER

Amphastar Pharmaceuticals Inc

21.150

-0.060-0.28%
詳細情報 Amphastar Pharmaceuticals Inc 企業名
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
企業情報
企業コードAMPH
会社名Amphastar Pharmaceuticals Inc
上場日Jun 25, 2014
最高経営責任者「CEO」Dr. Yongfeng (Jack) Zhang, Ph.D.
従業員数2028
証券種類Ordinary Share
決算期末Jun 25
本社所在地11570 6th St
都市RANCHO CUCAMONGA
証券取引所NASDAQ Global Select Consolidated
United States of America
郵便番号91730
電話番号19099809484
ウェブサイトhttps://amphastar.com/
企業コードAMPH
上場日Jun 25, 2014
最高経営責任者「CEO」Dr. Yongfeng (Jack) Zhang, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
74.45K
-0.67%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
+18.98%
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
Mr. Jacob Liawatidewi
Mr. Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director
--
--
Mr. Dan Dischner
Mr. Dan Dischner
Vice President - Corporate Communications
Vice President - Corporate Communications
--
--
Ms. Diane G. Gerst
Ms. Diane G. Gerst
Independent Director
Independent Director
--
--
Mr. David Gaugh
Mr. David Gaugh
Director
Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Rong Zhou
Mr. Rong Zhou
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
197.10K
+5.69%
Dr. Howard S. Lee, Ph.D.
Dr. Howard S. Lee, Ph.D.
Independent Director
Independent Director
148.90K
+2.90%
Mr. Floyd F. Petersen
Mr. Floyd F. Petersen
Independent Director
Independent Director
74.45K
-0.67%
Mr. William J. Peters
Mr. William J. Peters
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director
55.44K
-0.49%
Mr. Richard K. Prins
Mr. Richard K. Prins
Lead Independent Director
Lead Independent Director
32.11K
+18.98%
Ms. Gayle Deflin
Ms. Gayle Deflin
Independent Director
Independent Director
7.84K
+188.59%
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
United States
162.59M
95.35%
France
7.86M
4.61%
China
81.00K
0.05%
事業別
地域別
データなし
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
Applied Physics & Chemistry Laboratories, Inc.
14.48%
BlackRock Institutional Trust Company, N.A.
11.72%
Zhang (Jack Yongfeng)
5.57%
The Vanguard Group, Inc.
5.12%
TD Asset Management Inc.
4.32%
Other
58.79%
株主統計
株主統計
比率
Applied Physics & Chemistry Laboratories, Inc.
14.48%
BlackRock Institutional Trust Company, N.A.
11.72%
Zhang (Jack Yongfeng)
5.57%
The Vanguard Group, Inc.
5.12%
TD Asset Management Inc.
4.32%
Other
58.79%
種類
株主統計
比率
Investment Advisor
41.31%
Investment Advisor/Hedge Fund
22.63%
Corporation
14.48%
Individual Investor
9.20%
Hedge Fund
6.05%
Research Firm
1.44%
Pension Fund
0.97%
Bank and Trust
0.32%
Sovereign Wealth Fund
0.11%
Other
3.48%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
601
45.52M
96.57%
-3.82M
2025Q1
611
45.81M
97.08%
-3.30M
2024Q4
605
46.57M
97.74%
-2.04M
2024Q3
587
46.65M
96.28%
-609.11K
2024Q2
577
45.56M
93.11%
-1.23M
2024Q1
560
44.76M
91.63%
-1.31M
2023Q4
542
44.44M
92.40%
-767.71K
2023Q3
510
43.50M
90.64%
-1.16M
2023Q2
483
43.02M
88.37%
-388.11K
2023Q1
456
42.07M
87.29%
-710.60K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Applied Physics & Chemistry Laboratories, Inc.
6.83M
14.48%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.52M
11.72%
-66.62K
-1.19%
Mar 31, 2025
Zhang (Jack Yongfeng)
2.62M
5.57%
+200.00K
+8.25%
Jun 13, 2025
The Vanguard Group, Inc.
2.41M
5.12%
-291.72K
-10.78%
Mar 31, 2025
TD Asset Management Inc.
2.21M
4.69%
+371.86K
+20.21%
Mar 31, 2025
State Street Global Advisors (US)
1.60M
3.4%
+8.50K
+0.53%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.36M
2.88%
+157.77K
+13.16%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
1.26M
2.68%
+130.67K
+11.53%
Mar 31, 2025
Epoch Investment Partners, Inc.
1.26M
2.68%
+160.03K
+14.53%
Mar 31, 2025
Boston Trust Walden Company
1.22M
2.58%
+236.70K
+24.18%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Invesco Pharmaceuticals ETF
2.43%
SPDR S&P Pharmaceuticals ETF
1.92%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.36%
Invesco S&P SmallCap 600 GARP ETF
0.99%
Acquirers Small and Micro Deep Value ETF
0.92%
Invesco S&P SmallCap Health Care ETF
0.6%
iShares U.S. Pharmaceuticals ETF
0.42%
Distillate Small/Mid Cash Flow ETF
0.42%
First Trust Small Cap Value AlphaDEX Fund
0.41%
VictoryShares Small Cap Free Cash Flow ETF
0.39%
詳細を見る
Invesco Pharmaceuticals ETF
比率2.43%
SPDR S&P Pharmaceuticals ETF
比率1.92%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
比率1.36%
Invesco S&P SmallCap 600 GARP ETF
比率0.99%
Acquirers Small and Micro Deep Value ETF
比率0.92%
Invesco S&P SmallCap Health Care ETF
比率0.6%
iShares U.S. Pharmaceuticals ETF
比率0.42%
Distillate Small/Mid Cash Flow ETF
比率0.42%
First Trust Small Cap Value AlphaDEX Fund
比率0.41%
VictoryShares Small Cap Free Cash Flow ETF
比率0.39%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
tradingkey.logo
tradingkey.logo
当社が提供する日中データはRefinitivより配信されており、同社の利用規約が適用されます。終値データ(過去・現在)についてもRefinitivより提供されています。全ての相場情報は現地取引所時間で表示されます。米国株式のリアルタイム最終取引価格はNasdaqを通じて報告された取引のみを反映しています。日中データは最低15分遅れ、または各取引所の要件に準じて遅延配信されます。
* 当コンテンツ(分析資料・取引戦略等)は第三者プロバイダーであるTrading Centralより提供されており、記載の見解は分析官の独立した評価及び判断に基づくものです。投資家個々の投資目的や財務状況は考慮されておりません。
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。
KeyAI